INDIANAPOLIS, June 26, 2019 /PRNewswire/ -- Eli Lilly and Company's (NYSE: LLY) trial studying higher investigational doses of Trulicity ® (dulaglutide) met its primary efficacy endpoint of ...

The win puts Trulicity in a small group of GLP-1 drugs that have posted heart-helping benefits for patients. The thing is, Novo Nordisk’s weekly Ozempic—whose active ingredient, semaglutide ...

This decision makes Eli Lilly and Company's (NYSE: LLY) Trulicity the first and only type 2 diabetes medicine approved to reduce the risk of MACE for both primary and secondary prevention populations.

Shares of Eli Lilly & Co. fell 2.4% in premarket trade on Monday after a randomized control trial showed that diabetes drug Trulicity lowered the risk of major cardiovascular events in patients ...

Only 31 percent of those in the 9,901-patient study had heart disease, the company said. The trial compared 1.5 milligrams of Trulicity once a week to placebo, with the primary goal a reduction in ...

Lilly expands Trulicity marketing push, lowers 2015 guidance . The drugmaker says its Trulicity focus now includes primary care doctors in addition to specialists, and that foreign exchange will take ...